Empagliflozin in Heart Failure with a Preserved Ejection Fraction

Abstract

Empagliflozin reduced the combined risk of cardiovascular death or hospitalization for heart failure in patients with heart failure and a preserved ejection fraction, regardless of the presence or absence of diabetes. (Funded by Boehringer Ingelheim and Eli Lilly; EMPEROR-Preserved ClinicalTrials.gov number, NCT03057951).

Keywords

EmpagliflozinEjection fractionHeart failureCardiologyInternal medicineMedicineFraction (chemistry)Heart failure with preserved ejection fractionDiabetes mellitusChemistryEndocrinologyChromatographyType 2 diabetes

Affiliated Institutions

Related Publications

Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure

Milton Packer , Stefan D. Anker , Javed Butler +36 more

Among patients receiving recommended therapy for heart failure, those in the empagliflozin group had a lower risk of cardiovascular death or hospitalization for heart failure th...

2020 New England Journal of Medicine 4558 citations

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction

John J.V. McMurray , Scott D. Solomon , Silvio E. Inzucchi +35 more

BACKGROUND In patients with type 2 diabetes, inhibitors of sodium-glucose cotransporter 2 (SGLT2) reduce the risk of a first hospitalization for heart failure, possibly through ...

2019 New England Journal of Medicine 6238 citations

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes

Stephen D. Wiviott , Itamar Raz , Marc P. Bonaca +17 more

In patients with type 2 diabetes who had or were at risk for atherosclerotic cardiovascular disease, treatment with dapagliflozin did not result in a higher or lower rate of MAC...

2018 New England Journal of Medicine 5890 citations

Dapagliflozin in Patients with Chronic Kidney Disease

Hiddo J.L. Heerspink , Bergur V. Stefánsson , Ricardo Correa‐Rotter +11 more

Among patients with chronic kidney disease, regardless of the presence or absence of diabetes, the risk of a composite of a sustained decline in the estimated GFR of at least 50...

2020 New England Journal of Medicine 4549 citations

Prediction of Mortality and Morbidity With a 6-Minute Walk Test in Patients With Left Ventricular Dysfunction

Vera Bittner

<h3>Objective.</h3> —To study the potential usefulness of the 6-minute walk test, a self-paced submaximal exercise test, as a prognostic indicator in patients with left ventricu...

1993 JAMA 691 citations

Publication Info

Year: 2021
Type: article
Volume: 385
Issue: 16
Pages: 1451-1461
Citations: 4054
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Empagliflozin in Heart Failure with a Preserved Ejection Fraction

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

4054

OpenAlex

Cite This

APA Style

                            
                                
                                    Stefan D. Anker, 
                                
                                    Javed Butler, 
                                
                                    Gerasimos Filippatos
                                
                                et al.
                            
                            (2021). 
                            Empagliflozin in Heart Failure with a Preserved Ejection Fraction. 
                            New England Journal of Medicine
                            , 385
                            (16)
                            , 1451-1461.
                            https://doi.org/10.1056/nejmoa2107038
                        

Identifiers

DOI: 10.1056/nejmoa2107038